RBI is pleased to announce completion of a European distribution agreement with Equus MedicLine Europe bvba, a division of Equus Sport Europe, for distribution of VetriGel and other RBI veterinary products.;
FREDERICK, Md.–(BUSINESS WIRE)–Royer Biomedical, Inc. (RBI) received FDA approval to proceed with Human Testing of AppliGel-G (Gentamicin) in management of Diabetic Foot Ulcers (DFU). AppliGel is a patented proprietary dissolvable non-immunogenic Polymer Drug Delivery System Platform. It has demonstrated efficacy in biofilm and infection eradication, without significant systemic API levels. “This represents an important milestone in the development of AppliGel,” [...]
FREDERICK, Md.–(BUSINESS WIRE)—Royer Biomedical Inc. (RBI) was awarded a US patent covering the core technologies of its proprietary AppliGel dissolvable non-immunogenic Polymer Drug Delivery System Platform. The US Patent and Trademark Office allowed 53 claims broadly covering composition of matter, methods, commercial kits, and formulations. AppliGel Drug Delivery System Platform received pre-IND pathway concurrence earlier this year. The Company is [...]
